Norepinephrine Transporter Blockade, Autonomic Failure (NETAF)

Neurogenic Orthostatic Hypotension Clinical Trial

— NETAF  

Official title:

Phase 2 Norepinephrine Transporter Blockade, Autonomic Failure IND117394 12/28/12

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02784535
• Other study ID #: 160415
• Status: Completed
• Phase: Phase 2
• Start date: August 29, 2016
• Est. completion date: June 2023

Study information

• Verified date: August 2023
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic hypotension are scarce and not effective. If left untreated, these patients have the highest risk of syncope, falls and fall-related injuries. The proposed study will determine the clinical benefit of a commercially available drug, atomoxetine, to reduce symptoms associated with neurogenic orthostatic hypotension in patients with autonomic failure.

Description:

Autonomic failure is a group of rare neurodegenerative disorders that primarily affect the autonomic nervous system. These patients develop neurogenic orthostatic hypotension (OH) because of impaired autonomic reflexes that control cardiovascular and neuro-humoral adaptation to upright posture. The treatment of neurogenic OH is challenging; the therapeutic options are scarce, and some patients are refractory to treatment.

Atomoxetine is a selective norepinephrine transporter inhibitor that increases the availability of norepinephrine in the synapse by blocking its reuptake. Our preliminary data in sixty-five patients with primary autonomic failure and neurogenic OH showed that atomoxetine was more effective than midodrine, standard of care, in improving standing SBP (+7.5 mm Hg). Notably, only atomoxetine and not midodrine induced a significant reduction in OH-related symptoms (lightheadedness and dizziness) compared with placebo. In this proposal, we will test the hypothesis that prolonged administration of the norepinephrine transporter blocker, atomoxetine, improves OH-related symptoms and OH-impact on daily activities compared with placebo in autonomic failure patients. We propose a randomized, double-blind, placebo-controlled, 2x2 crossover study.

Other known NCT identifiers

• NCT02796209

Recruitment information / eligibility

• Status: Completed
• Enrollment: 48
• Est. completion date: June 2023
• Est. primary completion date: May 12, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years to 80 Years

Eligibility

Inclusion Criteria:

• 40 years old or older

• Neurogenic Orthostatic Hypotension (defined by a reduction of =20 mmHg drop in SBP within 3 minutes of standing, associated with impaired autonomic reflexes as assessed by autonomic function tests.

Exclusion Criteria:

• Pregnancy or breastfeeding

• Hypersensitivity to atomoxetine (severe allergic reaction, rash, urticaria, anaphylaxis)

• Use of other norepinephrine transporter inhibitors such as Wellbutrin (Bupropion), Cymbalta (Duloxetine), Effexor (venlafaxine), Pristiq (desvenlafaxine), Savella (milnacipran)

• Previous history (within 14 days prior to enrollment) and current use of monoamine oxidase inhibitors

• Concomitant use of strong CYP2D6 inhibitors such as delavirdine, paroxetine, fluoxetine, quinidine

• Pre-existing sustained severe hypertension (BP = 140/80 mmhg in the sitting position)

• Impaired hepatic function (aspartate amino transaminase [AST] and/or alanine amino transaminase [ALT] >2 x upper limit of normal range)

• Impaired renal function (serum creatinine equal or more than 1.6 mg/dl)

• Myocardial infarction within 6 months prior to enrollment

• Congestive heart failure (LV hypertrophy acceptable)

• History of serious neurologic disease such as cerebral hemorrhage, or stroke

• Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, unlikelihood of completing the study, and mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study

• Narrow-angle glaucoma

Related Conditions & MeSH terms

• Hypotension
• Hypotension, Orthostatic
• Neurogenic Orthostatic Hypotension
• Pure Autonomic Failure

Intervention

Drug:
• Atomoxetine
norepinephrine transporter inhibitor
• Placebo
placebo

Locations

Country	Name	City	State
United States	Vanderbilt University Medical Center	Nashville	Tennessee
United States	Dysautonomic Center at NYU Langone Medical Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center	NYU Langone Health

Country where clinical trial is conducted

United States, 

References & Publications (2)

Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, Raj SR, Robertson D, Biaggioni I, Shibao CA. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension. 2014 Dec;64(6):1235-40. doi: 10.1161/HYPERTENSIONAHA.114.04225. Epub 2014 Sep 2. — View Citation

Shibao C, Raj SR, Gamboa A, Diedrich A, Choi L, Black BK, Robertson D, Biaggioni I. Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function. Hypertension. 2007 Jul;50(1):47-53. doi: 10.1161/HYPERTENSIONAHA.107.089961. Epub 2007 May 21. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the OHQ (Orthostatic Hypotension Questionnaire) Composite Score	The Orthostatic Hypotension Questionnaire (OHQ) , patient-reported assessment tool consisting of the OH Symptom Assessment (OHSA), OH Daily Activity Scale (OHDAS).; The composite score is composed of 10 individual items: 6 items measure specific symptoms , the Orthostatic Hypotension Symptom Assessment (OHSA), and 4 items measure the impact of those symptoms on a patient daily activities, the Orthostatic Hypotension Daily Activity Scale (OHDAS). This scales helps to measure the impact of orthostatic symptoms on daily.; Scale is between 0-10: where "0" is minimum Orthostatic symptoms and "10" is the maximum / worse possible severity of the symptoms.; All items are scored 0 through 10 (higher scores = more impact) and summed into the respective total scores.; The OHSA and OHDAS subscales averaged to compute the OHQ composite score.	week 0 to week 4
Secondary	Change in Blood Pressure	Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) (measured in mm of Hg) , is recorded after 10 mins of standing. The changes SBP and DBP are compared from baseline, post drug (4 weeks)	Baseline to 4 weeks
Secondary	Change in Heart Rate (HR)	HR is compared to baseline after 10 mins of standing. The difference increase in Heart rate from baseline, post drug at 4 weeks	Baseline and at 4 weeks